ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
31 hedge funds and large institutions have $88.2M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 11 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
1% more capital inflows, than outflows
Capital inflows: $11.3M | Capital outflows: $11.2M
0.35% more ownership
Funds ownership: 39.68% → 40.03% (+0.35%)
24% less funds holding
Funds holding: 41 → 31 (-10)
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.02M |
| 2 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.16M |
| 3 |
Mangrove Partners
Greenwich,
Connecticut
|
+$1.05M |
| 4 |
Morgan Stanley
New York
|
+$586K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$356K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Luminus Management
Houston,
Texas
|
-$5.88M |
| 2 |
Monashee Investment Management
Boston,
Massachusetts
|
-$1.41M |
| 3 |
Logos Global Management
San Francisco,
California
|
-$938K |
| 4 |
Affinity Asset Advisors
New York
|
-$670K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$503K |
ASLN Hedge Fund Activity: Q2 2021 in Review
31 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q2 2021, worth a combined $88.2M — down 0.57% from $88.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ASLN and 1 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Citadel Advisors, adding an estimated $7.02M. The largest seller was Luminus Management, exiting entirely with an estimated $5.88M sold.
- 31 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q2 2021, down from 41 in Q1 2021.
- Funds reported $88.2M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q2 2021, down 0.57% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q2 2021 and 11 closed out, a net change of -10 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q2 2021 was Citadel Advisors, an estimated $7.02M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q2 2021 was Luminus Management, an estimated $5.88M sold.
Based on aggregated 13F filings for Q2 2021.